Clinical Trial: Comparing the Combination of Sullumab and Fruquintinib in Postoperative Adjuvant Therapy for High Recurrence Risk Non Transparent Renal Cell Carcinoma

U.S., March 24 -- ClinicalTrials.gov registry received information related to the study (NCT07488533) titled 'Comparing the Combination of Sullumab and Fruquintinib in Postoperative Adjuvant Therapy for High Recurrence Risk Non Transparent Renal Cell Carcinoma' on Jan. 19.

Brief Summary: This study is testing a new treatment approach for people who have had surgery to remove a type of kidney cancer called non-clear cell renal cell carcinoma (non-ccRCC). This kind of kidney cancer is different from the most common type and tends to come back after surgery, especially in high-risk patients.

After surgery, many patients are at risk of their cancer returning. Right now, there is no standard treatment to prevent this from happening. This study...